Live Breaking News & Updates on Iopharmaceutical

CStone Announces Oral Presentation at ESMO World GI 2023 for Pivotal Phase 3 Clinical Study of Sugemalimab in First-Line Esophageal Squamous Cell Carcinoma

China - CStone Pharmaceuticals , a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today. | June 13, 2023

Beijing , China , Tongji , Sichuan , United-kingdom , Spain , Barcelona , Comunidad-autonoma-de-cataluna , Qingshan-li , Hunan , Shanghai , Xianli

Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine

Vistagen , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system disorders,. | June 13, 2023

Trademark-office , European-patent-office , Vistagen-therapeutics , Nc-stock-exchange , News , Nformation , Ress-release , Vistagen , Ate , Iopharmaceutical , Ompany

DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023

SOUTH SAN FRANCISCO, Calif., June 13, 2023 DICE Therapeutics, Inc. , a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral. | June 13, 2023

New-york , United-states , Katie-engleman , Nasdaq , Therapeutics-inc , Dice-therapeutics , Nc-stock-exchange , News , Nformation , Ress-release , Outh , An

Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants

SAN DIEGO, June 13, 2023 Kura Oncology, Inc. , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced. | June 13, 2023

Spain , Boston , Massachusetts , United-states , New-york , Alexandra-weingarten , Bofa-securities-inc , Corporate-communications , Globenewswire-inc , Citizens-company , Nasdaq , Syndicate-department

Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share)

Ad hoc announcement pursuant to Art. 53 LR Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy , a rare,. | June 12, 2023

United-states , Switzerland , American , America , Mary-carmichael , Marlena-abdinoor , Swaminathans-clin , Julie-masow , Haresh-selvaskandan , Satoshi-sugimoto , Clin-nephrol , Richard-jarvis

First-in-class drug shows promise as a safe and effective treatment for cannabis use disorder

A first-in-class drug engineered to selectively inhibit the signaling pathway of the cannabinoid receptor shows promise as a safe and effective treatment for cannabis use disorder (CUD), a condition where a person is unable to control their cannabis use, even though it's causing problems in their lives.

United-states , France , District-of-columbia , French , Margaret-meg-haney , Francesr-levin , Vincenzo-piazza , Daelis-farma , Megan-craig , Neurocentre-magendie , Columbia-substance-use-research-center , Drug-administration

Disc Medicine Opco : Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress - Form 8-K

Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic. | June 9, 2023

Australia , Germany , Christina-tartaglia , John-quisel , Nasdaq , Verge-scientific-communications , Exchange-commission , European-hematology-association , Disc-medicine-inc , Disc-presents-positive-initial-data , Erythropoietic-protoporphyria , Chief-executive-officer

Abeona Therapeutics Shares Drop 7% After FDA Feedback for EB-101 BLA

By Chris Wack

Abeona Therapeutics shares were down 7%, to $3.99, after the clinical-stage biopharmaceutical company said Friday that it received feedback for a biologics license application. | June 9, 2023

Chris-wack , Indiana-university , Drug-administration , Dow-jones , Abeona-therapeutics-inc-stock-exchange , News , Nformation , Ress-release , Y , Hris , Ack , Abeona

NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares

NAARDEN, The Netherlands and MIAMI, June 09, 2023 NewAmsterdam Pharma Company N.V. , a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of. | June 9, 2023

Netherlands , Miami , Florida , United-states , Ukraine , Boston , Massachusetts , New-york , Naarden , Noord-holland , Russia , Van-lanschot-kempen

Phathom Pharmaceuticals Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

FLORHAM PARK, N.J., June 09, 2023 Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced. | June 9, 2023

United-states , Canada , New-york , Nick-benedetto , Nasdaq , Evercore-group , Equity-syndicate-prospectus-department , Needham-company , Phathom-pharmaceuticals , Exchange-commission , Phathom-pharmaceuticals-inc , Company-annual-report-on-form